Lineage Cell Therapeutics, Inc.Find Ratings Reports
LINEAGE CELL THERAPEUTICS IN's gross profit margin for the third quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. LINEAGE CELL THERAPEUTICS IN is extremely liquid. Currently, the Quick Ratio is 7.62 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 32.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY21||Q3 FY20|
|Net Sales ($mil)||2.27||0.57|
|Net Income ($mil)||-7.83||-7.76|
|Balance Sheet||Q3 FY21||Q3 FY20|
|Cash & Equiv. ($mil)||65.1||38.05|
|Total Assets ($mil)||131.21||103.09|
|Total Debt ($mil)||2.72||2.84|
|Profitability||Q3 FY21||Q3 FY20|
|Gross Profit Margin||56.61||82.14|
|Return on Assets||-9.14||-26.34|
|Return on Equity||-9.94||-29.76|
|Debt||Q3 FY21||Q3 FY20|
|Share Data||Q3 FY21||Q3 FY20|
|Shares outstanding (mil)||168.47||149.99|
|Div / share||0.0||0.0|
|Book value / share||0.72||0.61|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1191810.0||682535.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.57 indicates a significant discount versus the S&P 500 average of 4.63 and a significant discount versus the subsector average of 10.55. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, LINEAGE CELL THERAPEUTICS IN proves to trade at a discount to investment alternatives.
|LCTX NM||Peers 78.51||LCTX NM||Peers 20.90|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
LCTX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
LCTX's P/CF is negative making the measure meaningless.
|LCTX NM||Peers 18.35||LCTX NA||Peers 2.08|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
LCTX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|LCTX 2.57||Peers 10.55||LCTX 55.56||Peers 33.68|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
LCTX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
LCTX is expected to have an earnings growth rate that significantly exceeds its peers.
|LCTX 87.81||Peers 167.98||LCTX 30.08||Peers 396.18|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
LCTX is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
LCTX significantly trails its peers on the basis of sales growth.